Investment Rating - The report maintains an "Optimistic" rating for the industry and a "Buy" rating for Heng Rui Medicine (600276) [52] Core Insights - The newly released basic medical insurance drug directory and the first commercial health insurance innovative drug directory support the development of innovative drugs and promote the complementary relationship between commercial health insurance and basic medical insurance [9][12] - A total of 114 new drugs have been added to the directory, including 50 first-class innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [11][12] - The report emphasizes the importance of monitoring the volume growth of pharmaceutical companies' products after entering the insurance directory and the investment opportunities arising from the optimization of payment structures for innovative drug companies [51] Industry News - The new basic medical insurance drug directory and the first commercial health insurance innovative drug directory were published, with the new directory set to take effect on January 1, 2026 [9] - The first commercial health insurance innovative drug directory includes 19 drugs, which complement the basic medical insurance and support the establishment of a multi-tiered medical security system [12] - The first CDK2/4/6 inhibitor developed by China Biopharmaceutical has been approved for market launch, indicating advancements in innovative drug development [14] Company Announcements - Heng Rui Medicine has successfully included several drugs in the national medical insurance directory through negotiations, enhancing its market position [31] - Stone Pharmaceutical Group has received acceptance for its second marketing authorization application for Semaglutide injection [29] - Junshi Biosciences has had its new drug application for the injection of Nocadizumab accepted [32] Market Review - For the week of December 5 to December 11, 2025, the SW Pharmaceutical and Biological Index fell by 0.78%, with most sub-sectors experiencing declines [40] - As of December 11, 2025, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) was 50.70, with a valuation premium of 265% relative to the CSI 300 [44] Weekly Strategy - The report suggests focusing on the growth potential of pharmaceutical companies' products after entering the insurance directory and the investment opportunities in the CXO and upstream life sciences sectors [51]

Core Viewpoint - Heng Rui Medicine (600276) has seen a positive market response following the announcement of multiple drugs being included in the National Medical Insurance Directory for 2025, which is expected to enhance its revenue potential significantly [1]. Group 1: Stock Performance - As of December 8, 2025, Heng Rui Medicine closed at 62.46 CNY, up 1.36% from the previous trading day, with a total market capitalization of 414.56 billion CNY [1]. - The stock opened at 62.6 CNY, reached a high of 63.55 CNY, and a low of 61.92 CNY, with a trading volume of 3.187 billion CNY and a turnover rate of 0.8% [1]. Group 2: Drug Inclusion in National Insurance - Heng Rui Medicine announced that several of its drugs have been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Directory for 2025 [1]. - Newly included drugs are injection of Rukang Qutuzumab and Apixaban Famitin Capsules, while additional indications for drugs like injection of Karilizumab and Fluorouracil Capsules have also been added [1]. - The total sales for these drugs are projected to be approximately 8.66 billion CNY for the year 2024 and about 7.554 billion CNY for the first three quarters of 2025 [1]. - The new insurance directory will be implemented starting January 1, 2026, with specific payment standards to be announced officially [1].

Group 1 - The 7th United Nations Environment Conference will be held from December 8 to 12 in Nairobi, Kenya, aiming to inspire global collective action against climate change, pollution, and ecosystem degradation [2] - The revised "Securities Settlement Risk Fund Management Measures" will take effect on December 8, expanding the investment scope of the risk fund to include key term government bonds and other approved forms of fund utilization [2] - Jiahua Technology will resume trading on December 8, planning to issue shares and pay cash to acquire 90% of Shudun Information Technology and raise matching funds [2] - Annie Co., Ltd. will resume trading on December 8, with Shengshi Tianan becoming the controlling shareholder and gaining control of the company [2] Group 2 - ST Tianrui will resume trading on December 8, but the change of control matter has been terminated due to lack of consensus [3] - Nabichuan is available for subscription today with an issue price of 22.63 yuan and a price-to-earnings ratio of 28.70 times, with a subscription limit of 0.65 million shares, focusing on battery liquid cooling plates [3] - Youxun Co., Ltd. is available for subscription today with an issue price of 51.66 yuan and a price-to-earnings ratio of 60.27 times, with a subscription limit of 0.45 million shares, focusing on optical communication transceiver chips [3] Group 3 - The Financial Regulatory Bureau has announced adjustments to the risk factors for insurance companies' related business, which may release over 100 billion yuan into the market [5] - The China Securities Regulatory Commission is soliciting public opinions on the "Regulations on the Supervision and Administration of Listed Companies," which clarifies requirements for market value management, cash dividends, and share buybacks [5] Group 4 - The National Internet Information Office is soliciting public opinions on the "Network Data Security Risk Assessment Measures (Draft for Comments)" [6] - The National Medical Products Administration held an administrative guidance meeting on December 5 regarding online drug sales platforms, addressing prominent issues found in drug sales monitoring [6] - Shanghai has launched the first comprehensive traffic signal data open and application management service platform in a major city, with real-time data from 7,600 intersections to boost advanced autonomous driving research and production [6] - According to the China Construction Machinery Industry Association, excavator sales are expected to reach 20,027 units in November 2025, a year-on-year increase of 13.9%, with domestic sales of 9,842 units (up 9.11%) and exports of 10,185 units (up 18.8%) [6] Group 5 - The China Securities Regulatory Commission will appropriately relax regulations for quality institutions, aiming to enhance capital utilization efficiency [8] - Huachuang Securities believes the securities industry has shifted from a defensive contraction to an offensive expansion, opening up space for further ROE improvement [9] - The merger of Guotai Junan and Haitong Securities has been approved, with the third quarter showing a 136% year-on-year increase in revenue and a 101.52% increase in net profit [9] Group 6 - The market sentiment has improved, with major indices rising, and the adjustment of risk factors for insurance companies is expected to inject more liquidity into the market [11] - China Galaxy Securities anticipates that the upcoming policy window will provide direction for economic work in 2026 and indicate structural market trends [11] - Guotai Junan's merger effects are gradually becoming apparent, with significant revenue growth reported [11] Group 7 - The 2025 Cultivated Diamond Industry Conference was held, signing 30 projects with a total investment of no less than 15 billion yuan, and the market for cultivated diamonds is expected to exceed 102.5 billion yuan by 2030 [17] - Pacific Securities notes that the demand for diamond heat dissipation technology is increasing due to the rapid growth of AI and cloud computing technologies [17] - Related companies like Guoji Precision Engineering and Sifangda are actively pursuing opportunities in the diamond heat dissipation market [18]

Core Points - The company has successfully included several of its products in the National Medical Insurance Catalog for 2025, which is expected to enhance sales and improve operational performance [1] - The total estimated sales for the included drugs in 2024 is approximately 8.66 billion yuan, and for the first three quarters of 2025, it is about 7.55 billion yuan [1] Drug Inclusion in National Medical Insurance Catalog - The following drugs have been newly included: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Zhumab - Sulfate of Amatuximab Tablets - Injection of Phosphorola Pitant Palonosetron - Injection of Ruikasi Zhumab - Acetate of Abiraterone Tablets (II) - Lipid Injection of Irinotecan Hydrochloride (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following drugs have successfully added new indications: - Injection of Karelizumab - Fluorazepam Capsules - Injection of Fumaric Acid Tegafur [1] - The following drugs have been renewed and retained in the National Medical Insurance Catalog: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Methylsulfonylmethane Remazolam - Sulfate of Pevonedistat Injection [1] - The following drugs have new indications and have been adjusted to regular catalog management: - Mesylate of Apatinib Tablets - Lipid Injection of Bupivacaine [1] Impact on the Company - The inclusion of these drugs in the National Medical Insurance Catalog is expected to positively impact sales, although the exact effect on the company's operational performance is currently indeterminate [1] - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with further details on payment standards and reimbursement rules to be announced by relevant government departments [1]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has announced that several of its products have been included in the National Medical Insurance Directory, which is expected to positively impact sales and overall business performance in the future [1][2]. Group 1: Inclusion of Products in National Medical Insurance Directory - The following products have been newly included in the National Medical Insurance Directory: injection of Rukang Qutuzumab, Apixaban Famitinib capsules, injection of Funaqi Qutuzumab, Sulfate Amamxetine tablets, injection of Phosphororapitant Palonosetron, injection of Ruikasi monoclonal antibody, Acetate Abiraterone tablets (II), Liposomal Irinotecan injection (II), and Regaglitin Metformin tablets (I)/(II), as well as Perfluorohexyl Octane eye drops [2]. - Additional indications for injection of Karilizumab, Fluorouracil capsules, and injection of Fumagillin have successfully been added to the National Medical Insurance Directory [2]. - The renewal of the following products has been successfully retained in the National Medical Insurance Directory: Maleate Pyrrolidine tablets, Hecorapam Ethanolamine tablets, Phosphate Regaglitin tablets, injection of Toluene Sulfonate Remazolam, and Sulfate Pevotizumab injection [2]. Group 2: Financial Impact - The total sales of the aforementioned products for the year 2024 are estimated to be approximately 8.66 billion yuan, while the sales for the first three quarters of 2025 are projected to be around 7.55 billion yuan [2]. - The inclusion of these products in the National Medical Insurance Directory is expected to facilitate sales, although the exact impact on the company's operating performance cannot be estimated at this time [2].

Group 1 - Heng Rui Pharmaceutical has 9 drugs included in the national medical insurance directory for the first time, with an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 [5] - Junshi Biosciences' products Tuoyi® and Junshida® have been added to the national medical insurance directory, enhancing patient affordability and market promotion [6] - Huadong Medicine's subsidiary has products included in the national medical insurance and commercial insurance innovative drug directories, expected to aid in market promotion [7] Group 2 - Aidi Pharmaceutical's two innovative HIV drugs have successfully renewed their inclusion in the national medical insurance directory, with specific reimbursement prices set [8] - Fuxing Pharmaceutical has multiple products newly included in the national medical insurance directory, which is anticipated to positively impact future performance [9] - Weichuang Biotechnology's product has been included in the national medical insurance directory, which is expected to enhance market promotion and sales [10] Group 3 - Muxi Co., Ltd. announced a final online issuance rate of 0.03348913% after the mechanism was activated, with a total of 22.83 million shares issued [2] - Doushan New Materials reached a consensus on production reduction in the BOPET industry, although the sustainability of long-term price increases remains uncertain [2] - Guanglian Aviation's controlling shareholder has had the detention lifted, allowing normal operations to resume [3] Group 4 - Jiangjian Co., Ltd. clarified that it bears no obligations for any overdue financial products related to its controlling shareholder, confirming normal operations [4] - Tian Ci Materials' controlling shareholder has committed not to reduce holdings, holding 34.35% of the shares [13] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [14]

Core Viewpoint - Heng Rui Medicine has successfully included several of its products in the National Medical Insurance Catalog for 2025, which is expected to enhance sales and positively impact the company's performance in the future [1][2]. Group 1: Inclusion in National Medical Insurance Catalog - Heng Rui Medicine's products such as injection of Rukang Trastuzumab, Apixaban capsules, and others have been newly included in the National Medical Insurance Catalog [1]. - Additional indications for products like injection of Carrelizumab and Fluorouracil capsules have also been successfully added to the catalog [1]. - Existing products such as Pyrotinib tablets and others have successfully renewed their contracts to remain in the National Medical Insurance Catalog [1]. Group 2: Financial Impact - The total sales for the aforementioned drugs in 2024 are estimated to be approximately 8.66 billion yuan, while for the first three quarters of 2025, the sales are projected to be around 7.55 billion yuan [2]. - The impact on the company's operating performance due to the inclusion in the National Medical Insurance Catalog is currently indeterminate [2]. - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with further details on payment standards and reimbursement guidelines to be announced by relevant government departments [2].

Corporate Announcements - China Pacific Insurance announced that Vice President Yu Ze is under investigation for serious violations of discipline and law, but this will not affect the company's management [2] - Guanglian Aviation reported that its controlling shareholder and chairman Wang Zengduo has had his detention lifted, allowing him to resume his duties, with normal operations continuing [3] - China Communications Construction Company clarified that it bears no repayment or guarantee obligations related to overdue financial products linked to its controlling shareholder, and its operations remain normal [4] - Annie Co. is planning a change in control, with stock trading resuming on December 8, 2025, after a share transfer agreement is signed [5] - Guoao Technology announced that its actual controller is planning a change in control, leading to a temporary suspension of its stock [6] - ST Tianrui terminated its planned change in control due to a lack of consensus, with stock resuming trading on December 8, 2025 [7] Industry Developments - Double Star New Materials noted that leading companies in the BOPET industry have reached a consensus on production cuts to balance supply and demand, although the sustainability of long-term price increases remains uncertain [8] - First Venture received a notice of administrative penalty for failing to diligently supervise a bond project, resulting in fines and warnings, but this will not significantly impact its operations [12] - China Chemical announced that its nylon new materials project has reached full production capacity, enhancing efficiency and market competitiveness [14] Pharmaceutical Sector Updates - Hengrui Medicine reported that nine of its drugs have been included in the national medical insurance directory, with a total expected sales of approximately 8.66 billion yuan for 2024 [15] - Junshi Biosciences announced that its products have received new indications and have been included in the national medical insurance directory, enhancing market accessibility [16] - Huadong Medicine's subsidiary has had its products included in the national medical insurance and commercial insurance innovation drug directories, aiding market promotion [17] - Aidi Pharmaceutical's two innovative HIV drugs have been renewed for inclusion in the national medical insurance directory, with specific pricing established [18] - ZhiXiang JinTai's monoclonal antibody has been included in the national medical insurance directory, which is expected to positively impact future sales [19] - Fosun Pharma announced multiple products have been newly included in the national medical insurance directory, which is anticipated to positively influence future performance [20] - Zejing Pharmaceutical's drug has been included in the national medical insurance directory, which will enhance affordability and market promotion [21] - Micron Biologics' product has been included in the national medical insurance directory, with no significant impact on current performance expected [22] Shareholder Commitments - Tianci Materials' controlling shareholder has committed not to reduce his shareholding in the company for six months, reflecting confidence in the company's future [23] Major Contracts - Guangqi Technology's subsidiary signed contracts worth 696 million yuan for the mass production of metamaterials, expected to impact the company's performance in 2026 [24]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has successfully included several of its products in the National Medical Insurance Directory, which is expected to enhance market access and potentially increase sales revenue for the company [1] Group 1: Inclusion of Products - The following products have been newly included in the National Medical Insurance Directory: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Qutuzumab - Sulfate of Amagatin Tablets - Injection of Phosphororapitant Palonosetron - Injection of Ruikaxizumab - Acetate of Abiraterone Tablets (II) - Liposomal Injection of Irinotecan (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following products have successfully added new indications to the National Medical Insurance Directory: - Injection of Karilizumab - Fluorouracil Capsules - Injection of Fumaric Acid Tegafur [1] - The following products have successfully renewed their contracts to remain in the National Medical Insurance Directory: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Tofisopam - Injection of Sulfapegfilgrastim [1] Group 2: Adjustments and Management - The following products have had new indications added and adjusted to regular directory management: - Mesylate of Apatinib Tablets - Liposomal Injection of Bupivacaine [1]

Core Viewpoint - Heng Rui Medicine has successfully included several of its products in the National Medical Insurance Directory, which is expected to enhance sales and potentially improve the company's operational performance, although the exact impact remains uncertain [1][2]. Group 1: Inclusion in National Medical Insurance Directory - Heng Rui Medicine's products such as injection of Rukang Qutuzumab and others have been included in the National Medical Insurance Directory for 2025 [1]. - New indications for existing products like injection of Karilizumab and others have also been successfully added to the directory [1]. - Some products have retained their status in the directory, while others have had their indications adjusted to regular management [1]. Group 2: Financial Impact - The total sales for the aforementioned products are estimated to be approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [2]. - The implementation of the National Medical Insurance Directory will officially begin on January 1, 2026, with further details on payment standards and reimbursement to be announced by relevant government departments [2].